Boehringer Ingelheim has entered into a multi-year collaboration with Envisagenics, an AI drug discovery company, focused on oncology. The agreement has a potential value of about $1 billion, according to the announcement.
Under the pact, Envisagenics will use its AI platform to identify tumor-specific targets, while Boehringer will take on the task of validating those targets. The collaboration is structured around multiple targets, though specific diseases or mechanisms were not detailed in the source.
The deal reflects continued interest from large pharma in applying AI to early-stage target discovery. Boehringer's role in validation suggests a division of labor where AI generates hypotheses and traditional wet-lab work tests them.